

WELSH HEALTH SPECIALISED SERVICES COMMITTEE JOINT COMMITTEE MEETING – SEPTEMBER 2018

The Welsh Health Specialised Services Committee held its latest public meeting on 11 September 2018. This briefing sets out the key areas of discussion and aims to ensure everyone is kept up to date with what is happening in Welsh Health Specialised Services.

The papers for the meeting are available at:

http://www.whssc.wales.nhs.uk/2018-19-whssc-joint-committee

Action log & matters arising

Members noted the action log.

Chair's report

The Joint Committee received a written report that covered:

- The impending resignation of Lyn Meadows as Vice Chair due to changes in her portfolio at BCUHB;
- The appointment of Maggie Berry as a member of the WHSSC Quality & Patient Safety Committee;
- The appointment of Lyn Meadows as a member of the WHSSC Quality & Patient Safety Committee;
- The appointment of Dr Christopher D V Jones, CBE as a member and Vice Chair of the All Wales (WHSSC) Individual Patient Funding Review Panel; and
- Approval of revised Terms of Reference of the WHSSC Quality & Patient safety Committee.

Managing Director's report

The Joint Committee noted the content of the Managing Director's report and in particular updates on:

- Management Group Review: Members noted that the OD Team at CTUHB would be running an OD exercise with members of Management Group which would begin during autumn.
- Mother & Baby Unit for South Wales: WHSSC has received expressions of interest from two Health Boards to provide a Mother & Baby Service and is working with Public Health wales on demand and flow.

WHSSC Joint Committee Briefing Version: 1.0

Neonatal Transport: ABMUHB has expressed offered to act as lead provider.

Commissioning Intentions for 2019-22 Integrated Commissioning Plan

The Joint Committee received and approved a paper that outlined the options for Commissioning Intentions to inform the development of the WHSSC three year Integrated Commissioning Plan for Specialised Services 2019-22.

Introduction of Blueteq System for High Cost Drug Management The Joint Committee received a paper that described the potential use of Blueteg software in the commissioning of high cost drugs within NHS Wales.

Members (1) noted the benefits of introducing the Blueteq high cost drug management system across NHS Wales, including the commitment from the manufacturer to offer NHS Wales the same annual fee for the lifetime of the product and (2) approved recurrent funding for a system which supports both the seven Health Boards and WHSSC.

Terms of Reference – Integrated Governance Committee

The Joint Committee considered and approved Terms of Reference for the WHSSC Integrated Governance Committee.

WHSSC Sub-committee Annual Reports to the Joint Committee

The Joint Committee received and considered Annual Reports from the:

- Management Group;
- Integrated Governance Committee;
- All Wales (WHSSC) Individual Patient Funding Request Panel; and
- Welsh Renal Clinical Network.

Other reports

The Joint Committee received the Integrated Performance Report and Financial Performance Report. The Joint Committee also noted the update reports from the following joint sub committees and advisory groups:

- Management Group (Briefings);
- Integrated Governance Committee:
- All Wales (WHSSC) Individual Patient Funding Request Panel; and
- NHS Wales Gender Identity Partnership Group.









WHSSC Joint Committee Briefing Version: 1.0